abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Article

7 Feb 2006

Author:
Médecins Sans Frontières

Gilead's tenofovir 'access program' for developing countries: A case of false promises?

Tenofovir is now an important option for antiretroviral treatment for both AIDS patients starting therapy for the first time, and those that require access to newer drugs a few years down the line, particularly because it has fewer side effects than older antiretrovirals. As Gilead is the sole producer of tenofovir...MSF and others are dependent on the willingness of the company to make this urgently needed drug widely available. In...2002, Gilead announced that tenofovir would be available at a reduced price initially to 68, and then to 97 developing countries...Over three years later, tenofovir is registered for use in only six of these countries.

Timeline